These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27600335)

  • 1. iTRAQ-based proteomic analysis of plasma reveals abnormalities in lipid metabolism proteins in chronic kidney disease-related atherosclerosis.
    Luczak M; Formanowicz D; Marczak Ł; Suszyńska-Zajczyk J; Pawliczak E; Wanic-Kossowska M; Stobiecki M
    Sci Rep; 2016 Sep; 6():32511. PubMed ID: 27600335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry.
    Luczak M; Formanowicz D; Marczak Ł; Pawliczak E; Wanic-Kossowska M; Figlerowicz M; Stobiecki M
    J Transl Med; 2015 Jan; 13():20. PubMed ID: 25622820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease.
    Rysz-Gorzynska M; Gluba-Brzozka A; Banach M
    Curr Vasc Pharmacol; 2017; 15(2):144-151. PubMed ID: 27697068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan.
    Lin TH; Chuang SY; Chu CY; Lee WH; Hsu PC; Su HM; Li YH; Fang CC; Wang KY; Tseng WK; Li AH; Ueng KC; Hsieh IC; Huang LC; Wang CH; Pan WH; Yeh HI; Wu CC; Yin WH; Chen JW
    Int J Med Sci; 2014; 11(4):381-8. PubMed ID: 24578616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk.
    Dey R; Rajappa M; Parameswaran S; Revathy G
    Clin Exp Nephrol; 2015 Dec; 19(6):1054-61. PubMed ID: 25697595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
    Kon V; Yang H; Fazio S
    Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.
    Kimak E; Hałabiś M; Baranowicz-Gąszczyk I; Solski J; Książek A
    J Zhejiang Univ Sci B; 2011 May; 12(5):365-71. PubMed ID: 21528490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
    Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
    Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
    Rolla R; De Mauri A; Valsesia A; Vidali M; Chiarinotti D; Bellomo G
    J Nephrol; 2015 Dec; 28(6):749-55. PubMed ID: 25971848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker.
    Lepedda AJ; Nieddu G; Zinellu E; De Muro P; Piredda F; Guarino A; Spirito R; Carta F; Turrini F; Formato M
    Oxid Med Cell Longev; 2013; 2013():385214. PubMed ID: 24454983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.
    Maeba R; Kojima KI; Nagura M; Komori A; Nishimukai M; Okazaki T; Uchida S
    Atherosclerosis; 2018 Mar; 270():102-109. PubMed ID: 29407877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease.
    Honda H; Hirano T; Ueda M; Kojima S; Mashiba S; Hayase Y; Michihata T; Shibata T
    J Atheroscler Thromb; 2016; 23(1):81-94. PubMed ID: 26289085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
    Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
    [No Abstract]   [Full Text] [Related]  

  • 15. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease.
    Luczak M; Suszynska-Zajczyk J; Marczak L; Formanowicz D; Pawliczak E; Wanic-Kossowska M; Stobiecki M
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27144566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study.
    Lamprea-Montealegre JA; Sharrett AR; Matsushita K; Selvin E; Szklo M; Astor BC
    Atherosclerosis; 2014 May; 234(1):42-6. PubMed ID: 24607852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma apolipoprotein L1 levels do not correlate with CKD.
    Bruggeman LA; O'Toole JF; Ross MD; Madhavan SM; Smurzynski M; Wu K; Bosch RJ; Gupta S; Pollak MR; Sedor JR; Kalayjian RC
    J Am Soc Nephrol; 2014 Mar; 25(3):634-44. PubMed ID: 24231663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease.
    Rogacev KS; Zawada AM; Emrich I; Seiler S; Böhm M; Fliser D; Woollard KJ; Heine GH
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2120-7. PubMed ID: 25060791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.